Future work on dissecting the mechanisms using more comprehensive approaches on how IL-10 and/or nivolumab modulate anti-cancer immune responses in the context of the tumor microenvironment, will lead to identifying biomarkers and discovering more effective anti-cancer immunotherapies targeting IL-10 and PD-1. This evidence concerns the gene IL10 and cancer.